臨床泌尿器科62巻13号

2008年12月発行

綜説

前立腺癌に対する化学療法の現況と展望

著者： 野村威雄¹ 佐藤文憲¹ 三股浩光¹

所属機関： ¹大分大学医学部腫瘍病態制御講座〔泌尿器科〕

ページ範囲：P.1023 - P.1030

文献概要

要旨　前立腺癌は，病期にかかわらず化学療法に抵抗性の疾患である。特に，根治性の期待できない進行性前立腺癌は内分泌療法によるアンドロゲン遮断療法が治療の中心となる。しかし，転移を有する症例では内分泌療法の奏効期間は数年であり，ホルモン抵抗性再燃癌に変化する。ホルモン抵抗性再燃癌の有効な治療法は確立しておらず，唯一ドセタキセルを柱とした化学療法が生命予後を改善する可能性が報告されている。今後，本邦においてもドセタキセルが保険適用承認される予定であり，日常診療において標準治療となることが予想されるので，すべての泌尿器科医がドセタキセルを中心とした治療法を熟知する必要がある。本稿ではドセタキセルを使用した化学療法，さらにはドセタキセル抵抗性前立腺癌への二次化学療法について概説する。また，ハイリスク前立腺癌症例の外科的治療においてもドセタキセルによるネオアジュバントあるいはアジュバント療法が治療効果を向上させる可能性があり，併せて概説する。

参考文献

1）Tannock IF, de Wit R, Berry WR, et al：Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351：1502-1512, 2004

2）Petrylak DP, Tangen CM, Hussain MH, et al：Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351：1513-1520, 2004

3）Tannock IF, Osoba D, Stockler MR, et al：Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer：a Canadian randomized trial with palliative end points. J Clin Oncol 14：1756-1764, 1996

4）Kantoff PW, Halabi S, Conaway M, et al：Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer：results of the cancer and leukemia group B 9182 study. J Clin Oncol 17：2506-2513, 1999

5）Berthold DR, Pond GR, Soban F, et al：Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer：updated survival in the TAX327 study. J Clin Oncol 26：242-245, 2008

6）Hudes G, Einhorn L, Ross E, et al：Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer：a hoosier oncology group and fox chase network phase Ⅲ trial. J Clin Oncol 17：3160-3166, 1999

7）Kreis W, Budman DR, Fetten J, et al：Phase Ⅰ trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10：33-38, 1999

8）Petrylak DP, Macarthur RB, O'Connor J, et al：Phase Ⅰ trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17：958-967, 1999

9）Savarese DM, Halabi S, Hars V, et al：Phase Ⅱ study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer：a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 19：2509-2516, 2001

10）Sinibaldi VJ, Carducci MA, Moore-Cooper S, et al：Phase Ⅱ evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen-independent prostate carcinoma. Cancer 94：1457-1465, 2002

11）Kikuno N, Urakami S, Nakamura S, et al：Phase Ⅱ study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol 51：1252-1258, 2007

12）Eymard JC, Priou F, Zannetti A, et al：Randomized phase Ⅱ study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol 18：1064-1070, 2007

13）Bamias A, Bozas G, Antoniou N, et al：Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine：a single institution experience. Eur Urol 53：323-331, 2008

14）Rosenberg JE, Weinberg VK, Kelly WK, et al：Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients. Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110：556-563, 2007

15）Di Lorenzo G, Autorino R, Giuliano M, et al：Phase Ⅱ trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. Urology 69：347-351, 2007

16）Morant R, Bernhard J, Maibach R, et al：Response and palliation in a phase Ⅱ trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research（SAKK）. Ann Oncol 11：183-188, 2000

17）Saad F, Gleason DM, Murray R, et al：A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94：1458-1468, 2002

18）Vordos D, Paule B, Vacherot F et al：Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. BJU Int 94：524-547, 2004

19）Pettaway CA, Pisters LL, Troncoso P, et al：Neoadjuvant chemotherapy and hormone therapy followed by radical prostatectomy：feasibility and preliminary results. J Cin Oncol 18：1050-1057, 2000

20）Clark PE, Peereboom DM, Dreicer R, et al：Phase Ⅱ trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 57：281-285, 2001

21）Dreicer R, Magi-Galluzzi C, Zhou M, et al：Phase Ⅱ trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63：1138-1142, 2004

22）Febbo PG, Richie JP, George DJ, et al：Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11：5233-5240, 2005

23）Magi-Galluzzi C, Zhou M, Reuther AM, et al：Neoadjuvant docetaxel treatment for locally advanced prostate cancer：a clinicopathologic study. Cancer 15：1248-1254, 2007

24）Friedman J, Dunn RL, Wood D, et al：Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 179：911-916, 2008

25）Sella A, Zisman A, Kovel S, et al：Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. Urology 71：323-327, 2008

26）Prayer-Galetti T, Sacco E, Pagano F, et al：Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase Ⅱ trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int 100：274-280, 2007

27）Kibel AS, Rosenbaum E, Kattan MW, et al：Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy：a multi-institutional pilot study. J Urol 177：1777-1781, 2007

28）Roberts WW, Bergstralh EJ, Blute ML, et al：Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 57：1033-1037, 2001

29）Montgomery B, Lavori P, Garzotto M, et al：Veterans affairs cooperative studies program study 553：chemotherapy after prostatectomy, a phase Ⅲ randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer. Urology, 2008（in press）

30）Latif T, Wood L, Connell C, et al：Phase Ⅱ study of oral bis（aceto）ammine dichloro（cyclohexamine）platinum（Ⅳ）（JM-216, BMS-182751）given daily x 5 in hormone refractory prostate cancer（HRPC）. Invest New Drugs 23：79-84, 2005

31）Sternberg CN, Whelan P, Hetherington J, et al：Phase Ⅲ trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68：2-9, 2005

32）Calabro F and Sternberg CN：Current indications for chemotherapy in prostate cancer patients. Eur Urol 51：17-26, 2007

33）Sartor O, Sternberg C, Witjes JA, et al：Satraplatin significantly improves progression free survival（PFS）and pain control in patients with advanced hormone-refractory prostate cancer（HRPC）：preliminary results from the phase Ⅲ SPARC trial. AUA 2007：abstract 1014

34）Sternberg CN, Petrylak D, Witjes F, et al：Satraplatin（S）demonstrates significant clinical benefits for the treatment of patients with HRPC：results of a randomized phase Ⅲ trial. ASCO 2007：abstract 5019

35）Senzer N, Arsenau J, Richards D, et al：Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial. Am J Clin Oncol 28：36-42, 2005

36）Fiedler W, Tchen N, Bloch J, et al：A study from the EORTC new drug development group：open label phase Ⅱ study of sabarubicin（MEN-10755）in patients with progressive hormone refractory prostate cancer. Eur J Cancer 42：200-204, 2006

37）Mackler NJ, Dunn RL, Hellerstedt B, et al：Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. Cancer 106：2617-2623, 2006